Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)"중등도에서 중증의 COVID-19 환자에 대한 토실리주맙: 공개 라벨 다기관 무작위 통제" 시험(TOCIBRAS)의 근거 및 설계Original Article Published on 2020-01-012022-08-13 Journal: Revista Brasileira de Terapia Intensiva [Category] 임상, [키워드] 7-point ordinal scale adjusted age and sex alleviate Analysis anti-inflammatory therapies Anti-inflammatory therapy applied approved Brazil C reactive protein Clinical outcome clinical outcomes clinical status combating consequence Coronavírus COVID-19 COVID-19 patient COVID-19 patients criteria D-dimer disease severity dissemination enrolment ethical committee Ethics ferritin IMPROVE inflammatory cascade inflammatory mediator Inflammatory response inhibiting institutional review board institutional review boards interleukin-6 International Lactate lactate dehydrogenase limit Local mediator moderate to severe multicentre National Odds ratio Open-label ordinal logistic regression Ordinal Scale outcome patients patients with COVID-19 patients with moderate primary endpoint Pro-inflammatory marker pro-inflammatory markers protocol Randomized Randomized controlled trial rationale required severe COVID-19 severity Standard of care Stratification Study protocol the disease The TOCIBRAS protocol TOCIBRAS Tocilizumab Tocilizumabe Trial trial testing variable [DOI] 10.5935/0103-507X.20200060 PMC 바로가기 [Article Type] Original Article
Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case SeriesCOVID-19 치료를 위한 정맥 면역글로불린(Prevagen 또는 Octagam)의 사용: 후향적 사례 시리즈Observational Study Published on 2020-01-012022-09-11 Journal: Respiration [Category] MERS, 임상, 진단, 치료제, [키워드] acute respiratory distress acute respiratory distress syndrome administration Admission ARDS attenuate caused chronic Clinical course clinical courses clinical trial Comorbidity coronavirus coronavirus disease coronavirus disease 19 COVID-19 COVID-19 infection COVID-19 patient D-dimer demonstrated disease distress dose dose administration doses elevated evaluated hospital discharge Hospital stay ICU Illness severity Immunoglobulin immunomodulators IMPROVE Inflammatory response Inflammatory responses Intravenous immunoglobulin intravenous immunoglobulin. IVIG Mann-Whitney U test mechanical ventilation median median age median time men moderate moderate to severe occurred Patient patients with moderate Physiology ranged reduce reduce mortality regimen resources respiratory distress Respiratory distress syndrome score Sery Severe COVID-19 Infection significantly shorter Stage survived syndrome thrombotic thrombotic event Thrombotic events Treatment utilization Ventilation women [DOI] 10.1159/000511376 PMC 바로가기 [Article Type] Observational Study